Potent, orally active ATP-competitive transforming growth factor-β
receptor 1 (TGF-β
RI) inhibitor (IC50
= 49 nM). Displays > 100-fold and > 17-fold selectivity over TGF-β
RII and other common kinases respectively. Exhibits anti-inflammatory and antitumor activity. Also promotes an antiglioma immune response. Ameliorates germinal matrix hemorrhage-induced neurological deficits in neonatal rats.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
SD-208, a novel transforming growth factor β feceptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogeneicity of murine and human glioma cells in vitro and in vivo.
Uhl et al.
Cancer Res., 2004;64:7954
Transforming growth factor-β receptor type I receptor (TGFβRI) kinase activity but not p38 activation is required for TGFβRI-induced myofibroblast differentiation and profibrotic gene expression.
Kapoun et al.
Effect of transforming growth factor-β receptor I kinase inhibitor 2,4-disubstituted pteridine (SD-208) in chronic allergic airway inflammation and remodeling.
Leung et al.
Inhibition of transforming growth factor-β attenuates brain injury and neurological deficits in a rat model of germinal matrix hemorrhage.
Manaenko et al.
The citations listed below are publications that use Tocris products. Selected citations for SD 208 include:
Showing Results 1 - 2 of 2